Kathryn Wakeland
Emergency · Fort Worth, TXNPI 1184342339
Payments from drug & device makers
Across 271 payments — averaging $105.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$23K
- Novo Nordisk$729
- Lilly USA, LLC$662
- Dexcom, Inc.$443
- Neurocrine Biosciences, Inc.$376
- Xeris Pharmaceuticals, Inc.$358
- plus $3K from 34 others
What the payments were for
- Speaking & faculty fees$23,22781%
- Food & beverage$5,40619%
- Education$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 24 | $23,490 |
| Novo Nordisk | 39 | $729 |
| Lilly USA, LLC | 38 | $662 |
| Dexcom, Inc. | 20 | $443 |
| Neurocrine Biosciences, Inc. | 11 | $376 |
| Xeris Pharmaceuticals, Inc. | 15 | $358 |
| Sanofi-aventis U.S. LLC | 10 | $277 |
| Corcept Therapeutics | 9 | $216 |
| Tandem Diabetes Care, Inc. | 11 | $187 |
| Sequel Med Tech, LLC | 9 | $180 |
| Amgen | 7 | $158 |
| Alvogen Inc | 7 | $131 |
| Mannkind Corporation | 7 | $130 |
| AbbVie | 8 | $128 |
| Amneal Pharmaceuticals LLC | 6 | $113 |
| Chiesi USA, Inc. | 4 | $87 |
| Cequr Corporation | 2 | $79 |
| Novartis | 3 | $79 |
| Tolmar, Inc. | 4 | $67 |
| AstraZeneca | 3 | $66 |
| Madrigal Pharmaceuticals | 2 | $64 |
| Kyowa Kirin, Inc. | 3 | $63 |
| Ascendis Pharma Endocrinology Inc | 2 | $60 |
| Boehringer Ingelheim | 3 | $59 |
| Medtronic | 3 | $53 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $46 |
| IBSA Pharma Inc. | 2 | $41 |
| Halozyme Inc | 2 | $37 |
| Sandoz | 1 | $35 |
| Pfizer | 2 | $33 |
| Radius Health, Inc. | 2 | $33 |
| Bayer | 2 | $31 |
| Eisai Inc. | 1 | $26 |
| Aurinia Pharma U.S., Inc. | 1 | $21 |
| CSL Behring | 1 | $20 |
| Astellas Pharma US Inc | 1 | $19 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| Antares Pharma, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Vivus LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$23,371
- RECORLEV$133
- CRENESSITY$123
- Ozempic$111
How this compares
Too few emergency providers in Texasto place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 211 | $288,923 |
| OzempicSemaglutide | 99 | $140,655 |
| JardianceEmpagliflozin | 113 | $126,296 |
| TrulicityDulaglutide | 67 | $106,235 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $53,434 |
| Tresiba Flextouch U-100Insulin Degludec | 38 | $47,608 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 44 | $32,576 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 30 | $28,317 |
| FarxigaDapagliflozin Propanediol | 13 | $22,809 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $13,554 |
| Humalog Kwikpen U-100Insulin Lispro | 30 | $13,282 |
| SynjardyEmpagliflozin/Metformin Hcl | 12 | $10,219 |
| HumalogInsulin Lispro | 26 | $10,015 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $9,354 |
| NovologInsulin Aspart | 12 | $6,388 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $662 | $406,421317 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy | $59 | $164,831155 claims |
| Novo NordiskOzempic, Novolog | $729 | $147,043111 claims |
| AstraZenecaFarxiga | $66 | $22,80913 claims |
| AbbVieSynthroid | $128 | $3,31335 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $113 | $1,11262 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few emergency providers in Texason file to place this against a meaningful peer group, so we don't.
Other emergency in Fort Worth
- Karen ReillyGalveston$246
- Mark DinningHouston$45
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.